SkinCondition GuideAug 2026

Best Peptides for Acne in 2026

Most pages that rank peptides for skin rank them for collagen, then reuse the same list for acne. Acne is a different disease with four measurable drivers, and almost none of the popular peptides have been tested against any of them. This page ranks by what was measured, prints the queries that came back empty, and covers the peptides that plausibly push acne the wrong way.

PubMed records for GHK-Cu AND acne

Patients in the melanocortin acne pilot

Patients in the omiganan phase 2 trial

The first figure is a PubMed E-utilities search run on 8 August 2026 with the term GHK-Cu AND acne, which returned a count of zero. The second is the enrolment of a phase 2 open-label pilot of the alpha-MSH analogue afamelanotide in facial acne (PMID 22845050). The third is the randomised population of the omiganan atopic dermatitis trial (PMID 33010325), the largest controlled trial of a topical antimicrobial peptide in an inflammatory skin disease we could point to, and not an acne trial.

Read This First

Acne is a medical condition and no peptide is an approved treatment for it

We could not verify an approved acne indication for any peptide. The candidates with real acne development behind them, omiganan and melanocortin system agents, were described in 2017 as phase 1 and 2 investigational compounds, and we found no approval since (PMID 28627277). Persistent, painful or scarring acne belongs with a doctor. This page describes what research reports. It is not a protocol.

The treatments with the largest evidence base here are not peptides. A network meta-analysis of 221 randomised controlled trials across 37 interventions, with 65,601 patients in its primary total lesion analysis, ranked oral isotretinoin most effective, followed by triple therapy combining a topical antibiotic, a topical retinoid and benzoyl peroxide (Huang et al., Ann Fam Med 2023, PMID 37487721). Our adapalene guide and azelaic acid guide cover the two topical actives most often compared for this.

Four Drivers, And The Only Question Worth Asking

A pathogenesis review names four factors as playing vital roles in acne: hyperseborrhea and dysseborrhea, altered keratinization of the pilosebaceous duct, Cutibacterium acnes, and inflammation. It names androgens, insulin and IGF-1 as the main hormones responsible, and calls IGF-1 driven PI3K, Akt, FoxO1 and mTORC1 signalling the most important pathway in acne pathogenesis (Cong et al., Arch Dermatol Res 2019, PMID 30859308).

That gives one test for any peptide sold for acne. Which driver does it touch, in what model, and was the model a person?

Acne driver	Peptide studied against it	Highest model reached
Excess sebum	MC1R and MC5R antagonist	Human sebocytes, human skin on mice
Keratinization	Autophagy activating topical peptide	Randomised vehicle-controlled, acne-prone skin
C. acnes	Omiganan and other antimicrobial peptides	Randomised trials, but in other diseases
Inflammation	KdPT, an alpha-MSH derived tripeptide	SZ95 sebocyte cell line only

Note what is absent: the two peptides that top every skin ranking, GHK-Cu and BPC-157, appear against none of the four, because there is no acne study to place them in.

Ranked By Evidence, Not Popularity

Rank here means depth of published acne work, strongest first. It does not mean effectiveness, and nothing below has an approved acne indication we could verify.

Compound	Strongest acne-relevant evidence	What it does not show
Autophagy activating peptide, topical	8 week double-blind randomised vehicle-controlled study in acne-prone skin: fewer closed comedones, less surface lipid, lower water loss (PMID 32697858)	Acne-prone skin, not diagnosed acne. Enrolment not stated in the abstract. Company authors
Omiganan, topical	Two randomised controlled trials in skin disease, plus a review naming it an investigational anti-acne agent (PMID 33010325, 37762625, 28627277)	Both trials were in other diseases and both missed on clinical endpoints
Afamelanotide, alpha-MSH analogue	Phase 2 open-label pilot, 3 patients with mild to moderate facial acne, lesion counts fell in all 3 by day 56 (PMID 22845050)	3 patients, no control, no blinding. All also pigmented
KdPT, alpha-MSH derived tripeptide	Suppressed IL-1 beta induced IL-6 and IL-8 in SZ95 human sebocytes without binding MC1R (PMID 20610647)	Cell line only. No animal or human acne data found
LL-37 and beta-defensins	Host peptides central to acne pathogenesis research (PMID 39744637, 26695933)	What the disease produces, not a tested treatment
GHK-Cu, BPC-157, thymosin beta 4	None found. Each PubMed query paired with acne returned zero records on 8 August 2026	Nothing to rank. Popularity is not evidence

The top row is the closest thing to what people are asking for, and its limits travel with it: acne-prone skin rather than diagnosed acne vulgaris, closed comedones rather than a severity score, no enrolment figure in the abstract so we quote none, and authors affiliated with the developer (Lee et al., J Cosmet Dermatol 2021, PMID 32697858).

Antimicrobial Peptides: Best Logic, Worst Trial Record

If a peptide class should work here it is this one, since C. acnes is one of the four drivers. A 2024 review describes acne as involving microbiota dysbiosis, with raised expression of endogenous antimicrobial peptides such as beta-defensins, cathelicidin LL-37, dermcidin and RNase-7 as a hallmark, hypothesised as a compensatory response to an impaired permeability barrier (Lesiak et al., Front Immunol 2024, PMID 39744637). The lesion-level picture is less uniform than hallmark suggests: biopsies from 80 acne patients and 20 controls found cathelicidin differed only in the inflammation region, and was significantly low there in comedones (Ozlu et al., Cutan Ocul Toxicol 2016, PMID 26695933).

Then the trials. In 80 patients with mild to moderate atopic dermatitis randomised to topical omiganan 1%, 1.75% or 2.5% or vehicle twice daily for 28 days, dysbiosis was recovered in every omiganan group and cultured S aureus fell 93.5% with omiganan 2.5% versus vehicle, 95% CI minus 99.2 to minus 28.5%, p = 0.02. No significant clinical improvement was observed, and the authors concluded that selectively targeting the microbiome does not appear to be a successful strategy in that disease (PMID 33010325). In mild to moderate facial seborrheic dermatitis, four weeks of omiganan 1.75% was safe and well tolerated but did not significantly improve the disease or any biomarker versus placebo, while the comparator ketoconazole 2.00% did (PMID 37762625). A working comparator in the same trial is what makes a null result mean something.

Neither trial was in acne, so neither closes the question. What they show is that killing the bacteria did not fix the skin. Our LL-37 profile and KPV profile set out what each has and has not been studied for.

The Direction Problem Nobody Mentions

Melanocortin receptors MC1R and MC5R sit in human sebaceous glands, MC5R only in differentiated sebocytes, with expression tied to sebum production. Sebaceous lipids are down-regulated in MC5R-deficient mice, and alpha-MSH acts as a sebotropic hormone in rodents (Zhang et al., Eur J Pharmacol 2011, PMID 21215742). So the acne research went looking for a blocker. The MC1R and MC5R antagonist JNJ-10229570 dose-dependently inhibited sebaceous lipid production in cultured human sebocytes, and topically on human skin grafted onto SCID mice it markedly decreased sebum-specific lipids, gland size and a differentiation marker, similar to flutamide in the same system (Eisinger et al., J Dermatol Sci 2011, PMID 21602033).

Melanotan-1, melanotan-2 and afamelanotide are agonists, not antagonists

They activate the receptor class the sebum research is trying to block. That is not a claim they cause acne, and we found none: the query "melanotan" AND "acne vulgaris" returned zero records on 8 August 2026. It is a reason to distrust the reasoning that a melanocortin peptide must be good for skin because it is a skin peptide. See our melanotan-2 profile.

KdPT is the clearest sign researchers treat this as a real obstacle. Investigators studying alpha-MSH in acne stated it directly: its usefulness is hampered by lipid-inducing and pigment-inducing effects through melanocortin receptor activation. So they took KdPT, a tripeptide derivative of the C-terminal end of alpha-MSH, and showed it suppressed IL-1 beta induced IL-6 and IL-8 in SZ95 sebocytes, reduced NF-kappaB DNA binding, did not bind MC1R and failed to induce melanogenesis (Mastrofrancesco et al., J Immunol 2010, PMID 20610647). The design goal was to keep the anti-inflammatory half and delete the melanocortin half. Two precision points: that work used KdPT, a derivative, not KPV, and on 8 August 2026 the queries KPV AND sebocyte and "KPV" AND "acne vulgaris" each returned zero records, so the result does not transfer. And KdPT evidence stops at a cell line.

The picture is not one-directional, which is why this stays a description. A phase 2 open-label pilot gave the superpotent alpha-MSH analogue afamelanotide to 3 patients with mild to moderate facial acne. Total and inflammatory lesion counts fell in all 3 by day 56, quality of life improved in all 3, and the only adverse effect was mild short-term fatigue in one patient. All patients also became more pigmented, especially on the face, and the authors called for future trials (Böhm et al., J Eur Acad Dermatol Venereol 2014, PMID 22845050). Three patients, open label, no control. A signal to test, not a result to act on.

GHK-Cu And BPC-157, The Two Everyone Lists

On 8 August 2026 we ran these PubMed E-utilities queries and recorded the count returned for each: GHK-Cu AND acne returned 0, GHK AND acne[Title/Abstract] returned 0, BPC-157 AND acne returned 0, "BPC 157" AND acne returned 0, "thymosin beta 4" AND acne returned 0, and "TB-500" AND acne returned 0.

One related query returns something. "copper tripeptide" AND acne returned a single record: a 2025 open-label study of a scar gel in females with acne scars, reporting a 26.57% reduction in scar appearance at day 45, p less than 0.0001 (Patel et al., Cureus 2025, PMID 41001334). Four things belong beside that number. There is no control group. The product is a proprietary blend of copper tripeptide-1 with L-carnitine L-tartrate, alpha-glucosyl hesperidin and sodium hyaluronate, so nothing can be attributed to the peptide. Several authors are employed by the contract research company or the product company. And the same abstract reports skin roughness decreasing by 100.86% at day 21 and 161.62% at day 45, which cannot be a plain percentage of a baseline value, so the metric is not what the wording implies.

Acne scars and active acne are different targets anyway. GHK-Cu does have a published record in other skin contexts, covered in our topical GHK-Cu profile and our peptide serum guide. Neither of those records is an acne record.

Peptides That May Push Acne The Wrong Way

This search brings in two readers: one wants something to try, the other already takes a peptide and has noticed their skin got worse. The second is better served here, and the mechanism is the best documented part. IGF-1 activated the MAPK/ERK and PI3-kinase pathways in SEB-1 sebocytes, and blocking PI3-kinase blocked the IGF-1 induced rise in SREBP-1, the transcription of SREBP target genes, and sebocyte lipogenesis (Smith et al., J Invest Dermatol 2008, PMID 17989724). In people, a 34 subject case-control study found DHEAS, DHT and IGF-1 correlated positively with acne lesion counts in women, and that in both sexes with clinical acne the androgen effect on lesion counts depended on IGF-1. The same study found the age-adjusted mean IGF-1 difference between women with and without clinical acne did not reach statistical significance, so this is a correlation in a small sample (Cappel et al., Arch Dermatol 2005, PMID 15781674).

Growth hormone axis peptides raise exactly that hormone. A single subcutaneous injection of CJC-1295 raised mean plasma GH 2 to 10 fold for 6 days or more and mean plasma IGF-1 by 1.5 to 3 fold for 9 to 11 days, staying above baseline up to 28 days after multiple doses (Teichman et al., J Clin Endocrinol Metab 2006, PMID 16352683). Over 12 months in 65 adults aged 60 to 81, oral MK-677 significantly increased GH and IGF-1 to the levels of healthy young adults (Nass et al., Ann Intern Med 2008, PMID 18981485).

What that is and is not: acne was not among the measured endpoints in either trial. No trial has shown a growth hormone secretagogue causes acne and this page does not claim one does. What is on the record is that these compounds raise IGF-1, the hormone a pathogenesis review puts at the centre of acne signalling (PMID 30859308). If skin changed after starting one, that is a conversation with a doctor, not a reason to add another compound. Our growth hormone peptides guide covers the class.

GLP-1 receptor agonists come up constantly and the literature disagrees with itself. A retrospective cohort study reported GLP-1 receptor agonist use associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men (Cho et al., J Am Acad Dermatol 2025, PMID 39923849). A 2024 meta-analysis across 45 articles and six GLP-1 receptor agonists found no conclusive acne side effects for any of them, concluded the drugs are unlikely to be directly responsible, and proposed weight loss driven physiological and hormonal changes instead, naming the thin literature as its own limitation (Ogunremi et al., Int J Womens Dermatol 2024, PMID 38586157). Our GLP-1 side effects guide and hormones guide cover the wider picture.

What Has Been Measured In Vietnamese Patients

Both acne studies we found in Vietnamese patients tested a drug or a procedure, not a peptide. A longitudinal study at University Medical Center Ho Chi Minh City followed 52 patients with moderate to severe acne of prolonged course, most with scarring, through 6 to 8 weeks of low dose oral isotretinoin. Severity dropped. Plasma homocysteine rose and serum folic acid fell significantly against baseline, but both stayed within the normal range (Van et al., PMID 30745980).

For scarring, a prospective single centre study at the National Hospital of Dermatology and Venereology in Hanoi treated 31 patients with grade 2 to 4 atrophic acne scars using a microneedle derma roller weekly for three months. Mean Goodman and Baron grade fell from 3.29 plus or minus 0.59 at baseline to 1.77 plus or minus 0.57 two months after the final treatment, and mean Lipper and Perez score from 36.48 plus or minus 12.07 to 16.37 plus or minus 7.29, both p less than 0.05. Side effects were burning and erythema, very mild and recovering in 1 to 2 days, with no post-inflammatory hyperpigmentation noted (Minh et al., PMID 30745984). No control group, so read those as within-group change over time.

One reason tolerability carries extra weight in this region: a trial in 150 Chinese patients with grade II to III acne stated in its background that Asian skin types tend to be more highly pigmented and that many Asians share a predisposition toward postinflammatory hyperpigmentation (Tu et al., J Eur Acad Dermatol Venereol 2001, PMID 11843231). Our retinoid purge guide and skincare guide cover the routine side in a hot climate.

The Figures These Sources Actually State

Numbers get stripped of their source and repeated as protocols, so each is printed with the study it belongs to. None is a recommendation.

The phase 2 open-label afamelanotide acne pilot in 3 patients (Böhm et al., PMID 22845050) reported giving:

Afamelanotide 16 mg, subcutaneous sustained-release resorbable implant, with lesion counts assessed 56 days after the first injection.

Disclaimer: this describes what an open-label study in 3 patients administered. It is not a dose recommendation, not a schedule and not advice. Afamelanotide is a prescription product for a different indication.

The omiganan atopic dermatitis phase 2 randomised trial (PMID 33010325) randomised 80 patients to:

Topical omiganan 1%, 1.75% or 2.5%, or vehicle, twice daily for 28 days on all lesions.

Disclaimer: these are the concentrations tested in a trial that found no significant clinical improvement. Reported here for accuracy, not to copy. Omiganan is investigational.

The CJC-1295 randomised placebo-controlled ascending dose trials in healthy adults (Teichman et al., PMID 16352683) reported tolerability as best at:

30 or 60 micrograms per kilogram, subcutaneous, with mean plasma IGF-1 rising 1.5 to 3 fold for 9 to 11 days after a single injection.

Disclaimer: this appears because raising IGF-1 is the mechanism discussed above, not because it is something to take. Acne was not an endpoint in that trial and no dosing guidance is given or implied.

The Ho Chi Minh City low dose isotretinoin study in 52 acne patients (Van et al., PMID 30745980) reported treating at:

0.37 plus or minus 0.11 mg per kg per day of oral isotretinoin, over 6 to 8 weeks.

Disclaimer: oral isotretinoin is a prescription drug with pregnancy and monitoring requirements. This records what one study used and is not a protocol for anyone.

The Short Version

Acne is a medical condition and we could not verify an approved acne indication for any peptide.
Antimicrobial peptides have the best mechanistic case and the worst trial record. Omiganan cleared S aureus in atopic dermatitis without clinical improvement, and lost to ketoconazole in seborrheic dermatitis.
Acne research on melanocortins is chasing an MC1R and MC5R antagonist to suppress sebum. Melanotan-1, melanotan-2 and afamelanotide are agonists, the opposite direction.
KdPT was built to strip melanocortin receptor activity out of alpha-MSH because its lipid and pigment inducing effects were the obstacle. That evidence stops at a cell line, and KdPT is not KPV.
On 8 August 2026, PubMed queries pairing acne with GHK-Cu, BPC-157, thymosin beta 4 and TB-500 each returned zero records.
Growth hormone axis peptides raise IGF-1, which sits at the centre of acne signalling. No trial has shown they cause acne, and none measured it.
GLP-1 and acne has one cohort study finding an association in nondiabetic obese women and one meta-analysis finding no conclusive drug effect. They do not agree.
The only acne studies we found in Vietnamese patients tested low dose oral isotretinoin and microneedling.

Frequently Asked Questions

Is any peptide an approved treatment for acne?+

We could not find one. The peptide candidates with acne development behind them are investigational: a 2017 review of phase 1 and 2 acne trials, built from searches of the US National Institutes of Health and European Medicines Agency trial databases run on 6 January 2017, listed omiganan and agents affecting the melanocortin system among compounds under investigation (Zouboulis et al., Expert Opin Investig Drugs 2017, PMID 28627277). Acne is a medical condition and treatment decisions belong with a doctor.

Does GHK-Cu or BPC-157 do anything for acne?+

There is nothing published to cite. On 8 August 2026 the PubMed queries GHK-Cu AND acne, BPC-157 AND acne, "BPC 157" AND acne, "thymosin beta 4" AND acne and "TB-500" AND acne each returned zero records. The one record for "copper tripeptide" AND acne is a 2025 open-label study with no control group, testing a multi-ingredient scar gel in females with acne scars rather than active acne, with authors employed by the research and product companies and no participant count in the abstract (Patel et al., Cureus 2025, PMID 41001334). Absence of records is not proof a compound does nothing, but it does mean nobody selling these for acne is citing a study.

Are antimicrobial peptides a good acne treatment?+

The mechanism is reasonable and the controlled trials are not encouraging. In a phase 2 randomised trial, 80 patients with mild to moderate atopic dermatitis got topical omiganan 1%, 1.75% or 2.5% or vehicle twice daily for 28 days. Cultured Staphylococcus aureus fell 93.5% with omiganan 2.5% versus vehicle, 95% CI minus 99.2 to minus 28.5%, p = 0.02, and no significant clinical improvement was observed (Niemeyer-van der Kolk et al., J Am Acad Dermatol 2022, PMID 33010325). In facial seborrheic dermatitis, omiganan 1.75% did not improve the disease versus placebo while the comparator ketoconazole 2.00% did (Rousel et al., Int J Mol Sci 2023, PMID 37762625). Neither disease is acne, so neither result settles acne, but fixing the microbiology did not fix the skin in either test.

Can peptides make acne worse?+

It is a mechanistic concern, not a demonstrated effect, and the difference matters. A single subcutaneous dose of the GHRH analogue CJC-1295 raised mean plasma IGF-1 by 1.5 to 3 fold for 9 to 11 days in healthy adults (Teichman et al., J Clin Endocrinol Metab 2006, PMID 16352683), and oral MK-677 raised IGF-1 into the young adult range over 12 months in 65 older adults (Nass et al., Ann Intern Med 2008, PMID 18981485). IGF-1 correlated with acne lesion counts in women in a 34 subject case-control study (Cappel et al., Arch Dermatol 2005, PMID 15781674) and drives sebocyte lipogenesis via PI3-kinase, Akt and SREBP-1 (Smith et al., J Invest Dermatol 2008, PMID 17989724). Acne was not among the measured endpoints in either peptide trial, so no trial has shown these cause acne, and none has ruled it out.

Should LL-37 go on acne skin?+

That inverts what the literature describes. LL-37 is a cathelicidin your own skin makes, and a 2024 review calls raised expression of endogenous antimicrobial peptides a hallmark of acne vulgaris, hypothesising it as a compensatory response to an impaired permeability barrier rather than a deficiency to top up (Lesiak et al., Front Immunol 2024, PMID 39744637). Biopsies from 80 acne patients and 20 controls found cathelicidin differed only in the inflammation region, and was significantly low in the inflammation region of comedones (Ozlu et al., Cutan Ocul Toxicol 2016, PMID 26695933). In rosacea, injecting the cathelicidin forms found in that disease into mouse skin increased inflammation (Yamasaki et al., Nat Med 2007, PMID 17676051).

What has been measured in Vietnamese acne patients?+

Drugs and procedures, not peptides. A longitudinal study at University Medical Center Ho Chi Minh City followed 52 patients with moderate to severe acne through 6 to 8 weeks of low dose oral isotretinoin and reported reduced disease severity, with homocysteine and folic acid changes that stayed inside the normal range (Van et al., Open Access Maced J Med Sci 2019, PMID 30745980). For scarring, 31 patients with grade 2 to 4 atrophic acne scars treated weekly for three months with a microneedle derma roller at the National Hospital of Dermatology and Venereology in Hanoi went from a mean Goodman and Baron grade of 3.29 to 1.77 two months after the final session, p less than 0.05, in a study with no control group (Minh et al., Open Access Maced J Med Sci 2019, PMID 30745984). We found no peptide trial in a Vietnamese acne population.

Sources

PubMed E-utilities esearch queries run 8 August 2026, counts as returned: GHK-Cu AND acne (0), GHK AND acne[Title/Abstract] (0), BPC-157 AND acne (0), "BPC 157" AND acne (0), "thymosin beta 4" AND acne (0), "TB-500" AND acne (0), "KPV" AND "acne vulgaris" (0), KPV AND sebocyte (0), "melanotan" AND "acne vulgaris" (0), "copper tripeptide" AND acne (1).
Cong TX et al. Arch Dermatol Res 2019. PMID 30859308.
Lesiak A et al. Front Immunol 2024. PMID 39744637.
Ozlu E et al. Cutan Ocul Toxicol 2016. PMID 26695933.
Niemeyer-van der Kolk T et al. J Am Acad Dermatol 2022. PMID 33010325.
Rousel J et al. Int J Mol Sci 2023. PMID 37762625.
Zouboulis CC et al. Expert Opin Investig Drugs 2017. PMID 28627277.
Zhang L et al. Eur J Pharmacol 2011. PMID 21215742.
Eisinger M et al. J Dermatol Sci 2011. PMID 21602033.
Mastrofrancesco A et al. J Immunol 2010. PMID 20610647.
Böhm M, Ehrchen J, Luger TA. J Eur Acad Dermatol Venereol 2014. PMID 22845050.
Lee Y et al. J Cosmet Dermatol 2021. PMID 32697858.
Patel MN et al. Cureus 2025. PMID 41001334. Open-label, no control group, multi-ingredient product, enrolment not stated in the abstract.
Smith TM et al. J Invest Dermatol 2008. PMID 17989724.
Cappel M, Mauger D, Thiboutot D. Arch Dermatol 2005. PMID 15781674.
Teichman SL et al. J Clin Endocrinol Metab 2006. PMID 16352683.
Nass R et al. Ann Intern Med 2008. PMID 18981485.
Cho SW et al. J Am Acad Dermatol 2025. PMID 39923849.
Ogunremi OO et al. Int J Womens Dermatol 2024. PMID 38586157.
Yamasaki K et al. Nat Med 2007. PMID 17676051.
Huang CY et al. Ann Fam Med 2023. PMID 37487721.
Van TLT et al. Open Access Maced J Med Sci 2019. PMID 30745980.
Minh PPT et al. Open Access Maced J Med Sci 2019. PMID 30745984.
Tu P et al. J Eur Acad Dermatol Venereol 2001. PMID 11843231.